Stockreport

Analysts Are Upgrading LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Its Latest Results [Yahoo! Finance]

LENZ Therapeutics, Inc.  (LENZ) 
PDF Revenues of US$13m beat estimates by a substantial 169% margin. Unfortunately, LENZ Therapeutics also reported a statutory loss of US$0.59 per share, which at least was [Read more]